Jazz Pharmaceuticals (JAZZ) said Friday it has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for zanidatamab to treat adults with unresectable locally advanced or metastatic HER2-positive biliary tract cancer.
The recommendation for the conditional marketing authorization of the investigational monotherapy in the European Union is backed by data from a phase 2b trial of patients previously treated with systemic therapy, according to the biopharmaceutical company.
The European Commission is expected to make a final decision based on the Committee's recommendation, Jazz Pharmaceuticals said.
JAZZ shares were edging 0.6% higher in recent trading.
Price: 109.58, Change: +0.60, Percent Change: +0.55
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。